{
    "clinical_study": {
        "@rank": "14789", 
        "acronym": "INSIGHTS-IPF", 
        "brief_summary": {
            "textblock": "Idiopathic pulmonary fibrosis (IPF), a manifestation of chronic progressive fibrosing\n      interstitial pneumonia,ia a rare disease. Current treatment options are limited, and the\n      mean survival time of the newly diagnosed (mostly elderly) patients is only about 2-3 years.\n      As in Europe data are limited on the characteristics and management of such patients,\n      INSIGHTS-IPF was initiated as a new registry that documents newly diagnosed (incident) and\n      prevalent patients with confirmed IPF diagnosis prospectively.The registry will contribute\n      to the optimization of the management of IPF patients in the long term."
        }, 
        "brief_title": "Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (IPF)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Idiopathic Pulmonary Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Fibrosis", 
                "Pulmonary Fibrosis", 
                "Idiopathic Pulmonary Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "INSIGHTS-IPF will report current and comprehensive data on Idiopathic Pulmonary Fibrosis\n      (IPF) in the long-term.\n\n      Baseline (cross-sectional part): Description of characteristics of IPF patients in terms of\n\n        -  key (socio-) demographic data\n\n        -  IPF risk factors, comorbidities\n\n        -  methods used for IPF diagnosis\n\n        -  IPF disease severity and manifestation (including lung function,    cardiopulmonary\n           exercise testing and/or exercise capacity if available, laboratory values, biomarkers)\n\n        -  IPF treatment (detailed information on prescribed drugs and doses; non-pharmacological\n           treatment; listing and score for lung transplantation)\n\n        -  assessment of patient-related outcomes (PRO) such as quality of life\n\n      Follow-up (prospectively up to at least 2 years after inclusion):\n\n        -  Clinical course of IPF (e.g. in terms of symptoms, lung function, exercise capacity if\n           available)\n\n        -  Documentation of treatment pathways (switch/add-on/discontinuation of medication), and\n           of non-pharmacological treatment (e.g. start of long term oxygen therapy; new listing\n           for lung transplantation)Outcomes/events (such as acute respiratory worsening,\n           exacerbations, hospitalisation due to any cause and due to IPF, other complications,\n           survival)\n\n        -  Patient-related outcomes such as quality of life, assessed once a year(for comparison\n           with baseline)\n\n        -  Resource use for pharmacoeconomic analyses."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years of age\n\n          -  Written informed consent for participation in the registry\n\n          -  Newly diagnosed (incident) or known (prevalent) IPF (based on diagnosis of treating\n             physician)\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with Idiopathic Pulmonary Fibrosis (confirmed diagnosis according to current\n        ATS/ERS guidelines)"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695408", 
            "org_study_id": "INSIGHTS-IPF"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Drug Treatment", 
            "Treatment pathways", 
            "Clinical routine", 
            "Registry", 
            "Outcomes", 
            "Survival", 
            "Patient-related outcomes", 
            "Quality of life", 
            "Steroids", 
            "Azathioprine", 
            "N-Acetylcysteine", 
            "Pirfenidone", 
            "Tyrosine kinase inhibitors", 
            "Nintedanib", 
            "multicenter", 
            "Germany", 
            "Safety", 
            "Adverse event"
        ], 
        "lastchanged_date": "January 31, 2014", 
        "link": {
            "description": "Study website", 
            "url": "http://insights-ipf.de"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Jurgen Behr, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bochum", 
                        "country": "Germany"
                    }, 
                    "name": "Klinik III f\u00fcr Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Berufs\u00acgenossen-schaftliches Universit\u00e4tsklinikum Bergmannsheil GmbH"
                }, 
                "investigator": {
                    "last_name": "Juergen Behr, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01307"
                    }, 
                    "name": "Institute for Clinical Pharmacology, Medical Faculty, Technical University"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "pneumologie@mh-hannover.de", 
                    "last_name": "Marius Hoeper, MD", 
                    "phone": "+49511 532", 
                    "phone_ext": "3934"
                }, 
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany"
                    }, 
                    "name": "Klinik f\u00fcr Pneumologie, Medizinische Hochschule Hannover"
                }, 
                "investigator": {
                    "last_name": "Marius M Hoeper, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "michael.kreuter@thoraxklinik-heidelberg.de", 
                    "last_name": "Michael Kreuter, MD", 
                    "phone": "+496221396", 
                    "phone_ext": "1214"
                }, 
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "69126"
                    }, 
                    "name": "Pneumologie und Beatmungsmedizin, Thoraxklinik,Universit\u00e4tsklinikum"
                }, 
                "investigator": {
                    "last_name": "Michael Kreuter, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hubert.wirtz@medizin.uni-leipzig.de", 
                    "last_name": "Hubert Wirtz, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany"
                    }, 
                    "name": "Abteilung f\u00fcr Pneumologie Department Innere Medizin, Neurologie und Dermatologie Universit\u00e4tsklinikum Leipzig A\u00f6R"
                }, 
                "investigator": {
                    "last_name": "Hubert Wirtz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Investigating Significant Health Trends in IPF (INSIGHTS-IPF). Nationwide Prospective Registry.", 
        "overall_contact": {
            "email": "j.behr@asklepios.com", 
            "last_name": "Juergen Behr, MD", 
            "phone": "089 85791", 
            "phone_ext": "4101"
        }, 
        "overall_contact_backup": {
            "email": "david.pittrow@mailbox.tu-dresden.de", 
            "last_name": "David Pittrow, MD", 
            "phone": "49 351 458", 
            "phone_ext": "2815"
        }, 
        "overall_official": [
            {
                "affiliation": "Institute for Clinical Pharmacology, Medical Faculty, Technical University Dresden, Germany", 
                "last_name": "Wilhelm Kirch, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Asklepios Fachkliniken M\u00fcnchen Gauting Medizinischen Klinik und Poliklinik V Klinikum der Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen  Comprehensive Pneumology Center Munich (CPC-M)  Mitglied des Deutschen Zentrums f\u00fcr Lungenforschung (DZL)", 
                "last_name": "Juergen Behr, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institute for Clinical Pharmacology, Medical Faculty, Technical University Dresden", 
                "last_name": "David Pittrow, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "reference": {
            "PMID": "23188642", 
            "citation": "Behr J, Hoeper MM, Kreuter M, Klotsche J, Wirtz H, Pittrow D. [Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry]. Dtsch Med Wochenschr. 2012 Dec;137(49):2586-8. doi: 10.1055/s-0032-1327244. Epub 2012 Nov 27. Review. German."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695408"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Technische Universit\u00e4t Dresden", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "GWT-TUD GmbH", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Boehringer Ingelheim", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Technische Universit\u00e4t Dresden", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}